These are enzalutamide, tacrolimus and patisiran, three drugs marketed by only two laboratories.

The estimated maximum value of the contracts is 17,897,908.27 euros.

The Consell de Govern has authorised the director general of the Health Service to contract the supply of three exclusive medicines. These are enzalutamide 40 mg tablets, tacrolimus 5 mg/ml injectable and patisiran 2 mg/ml injectable.

TDB keeps you informed. Follow us on Facebook, Twitter and Instagram

The Health Service contracts the supply of three unique drugs

Enzalutamide is used to treat adult men with prostate cancer who have stopped responding to hormone therapy or testosterone-lowering surgery. Tacrolimus belongs to a group of drugs known as immunosuppressants. After an organ transplant (liver, kidney, heart, etc.), the body’s immune system tries to reject the new organ. This drug is used to control the body’s immune response and allows it to accept the transplanted organ. Patitisiran is used to treat an inherited disease called hereditary amyloidosis (ATTR).

The estimated maximum value of the contracts is €17,897,908.27 for a period of 24 months from the date indicated in the contract, with the possibility of extension for a further 24 months.

Exclusive medicines are those for which there is no competition because the patents of the laboratories supplying them have not yet expired.

Health service facilities must be provided with the necessary medicines to be able to treat patients in order to guarantee the proper functioning of the health care activity.